Lexaria Bioscience Corp.
LEXX · NASDAQ
5/31/2025 | 2/28/2025 | 11/30/2024 | 8/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | -5.4% | 119% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 98.5% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,155.4% | -1,581% | -1,463% | -2,622.7% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,177.6% | -1,559.3% | -1,470% | -2,600.9% |
| EPS | -0.21 | -0.15 | -0.16 | -0.17 |
| % Growth | -40% | 6.3% | 5.9% | – |
| EPS Diluted | -0.21 | -0.15 | -0.16 | -0.17 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,137.6% | -1,579.7% | -1,444.9% | -2,621.4% |